
    
      This is a single arm clinical trial in subjects with advanced solid tumor receiving multiple
      doses of YH002 intravenously (IV). YH002 will be administered (IV) in 6-48 patients with
      advanced solid tumors. An accelerated titration method followed by a traditional 3+3 dose
      escalation algorithm will be utilized to determine MTD/MAD. Patients will be dosed at Dose A,
      Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H every 3 weeks (Q3W).
    
  